PharmaShots Weekly Snapshots (October 25 – 29, 2021)
ADC Reports EMA’s Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma Published: 29 Oct, 2021 | Tags: ADC, EMA, MAA, Zynlonta, […]
ADC Reports EMA’s Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma Published: 29 Oct, 2021 | Tags: ADC, EMA, MAA, Zynlonta, […]
Shots: Ginkgo is eligible to receive up front, R& D fees including milestones in the form of Selecta common stock, clinical & commercial milestones of […]
LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis Published: 22 Oct, 2021 | Tags: LEO, […]
Shots: Genovis to receive up front for an exclusive license to Xork & is eligible to receive development & sales-based milestones along with royalties on […]
Shots: Selecta to receive up front and ~$1.124B upon the achievement of development or commercial milestones or Takeda’s election continue its activities at specified development […]
Copyright © 2024 | WordPress Theme by MH Themes